Revvity Beats Q4 Estimates, Forecasts Strong 2026 on Diagnostics Momentum

Medical equipment maker Revvity delivered a strong fourth-quarter performance, beating estimates and forecasting 2026 revenue and profit above Wall Street expectations, driven by sustained momentum in its diagnostics business despite continued weakness in academic research funding.

Life sciences companies are benefiting from improving conditions in the pharmaceutical market and easing policy uncertainty, which have helped offset subdued spending by universities and research institutions.

As per media reports, Revvity now expects adjusted earnings per share for 2026 to range between $5.35 and $5.45, compared with analysts’ estimates of $5.32. The company also projected annual revenue of $2.96 billion to $2.99 billion, surpassing market expectations of $2.93 billion.

The diagnostics division emerged as the standout performer in the quarter ended December 28, posting 7% organic growth and generating revenue of $390.1 million, well above analysts’ estimates of $377.7 million. The unit provides testing tools for applications such as genetic screening.

Meanwhile, the life sciences segment, which supplies reagents and instruments used in drug discovery, reported quarterly revenue of $382 million, slightly below estimates of $385.6 million.

On the bottom line, Revvity reported adjusted earnings of $1.70 per share for the quarter, beating estimates of $1.55 per share. Quarterly revenue rose to $772.1 million, exceeding analysts’ expectations of $761.3 million.

Also Read